


## **Supplementary appendix**

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.


# Progression Free Survival

With Number of Subjects at Risk




# Overall Survival

With Number of Subjects at Risk



# Overall Survival of Chemotherapy Naive Patients

With Number of Subjects at Risk



## **webappendix Figure 1 legend**

*webappendix Figure 1:* (A) There was a trend (not statistically significant) toward improved progression-free survival in chemotherapy naïve patients treated at the 10-mg/kg dose level relative to lower dose levels. Similar trends in overall survival were seen among all patients (B) and those with no prior chemotherapy (C).